A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

NCT06326060 · Completed

Last updated 2026-05-28

This study is testing different doses of the medicine NN0519-0130 to see how well it helps people with obesity lose weight.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 354 people

Who can join Ages 18–75 · all sexes

Timeline Started 2024-03 · est. completion 2025-05

Where 70 sites · Australia, Japan, United States

What this study is testing ClinicalTrials.gov NCT06326060 ↗

Description as written by the study sponsor.

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.

Treatments tested

NNC0519-0130 Drug

NNC0519-0130 will be administered subcutaneously.
Placebo Drug

Placebo will be administered subcutaneously.
Tirzepatide Drug

Tirzepatide will be administered subcutaneously.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06326060 ↗